Crown Laboratories Inc., a privately held skincare company, and Revance Therapeutics, Inc., a biotechnology company aimed at setting a new standard in healthcare with innovative aesthetic and therapeutic offerings, have entered into a merger agreement pursuant to which the companies seek to merge the two complementary organizations.   Following completion of the merger, Revance will be wholly owned by Crown and Revance’s stock will no longer be publicly traded on Nasdaq.   Under the te...